Vyripharm Enterprises and CSU Pueblo have partnered up to create a comprehensive testing and certification laboratory that will provide the first consistent scientific analysis within cannabinoid research.
Vyripharm Enterprises, Inc. (VEI), a Texas biopharmaceutical/ biotechnology company based in the Texas Medical Center (TMC) and CSU Pueblo, the host site for the Institute of Cannabis Research (ICR), signed a Sponsored Research and Facilities Agreement (SRA) to support the creation of the new lab. Research within the lab will be carried out through the ICR, the nation’s first multi-disciplinary cannabis research center at a regional, comprehensive institution.
Under the terms of the agreement, VEI will provide intellectual property, equipment, and associated funds. A goal of this collaboration is to support a regulatory framework and standardization process in the state of Colorado, under the guidance of public health and public safety. The SRA has an initial term of 3 years, with automatic annual extensions. The laboratory is expected to be operational by the end of 2022.
“Consistency of cannabinoid analysis continues to be an issue in cannabinoid research and testing,” said Dr. Chad Kinney, director of the Institute of Cannabis Research. “We are excited to partner with Vyripharm on this endeavor and to serve as the site for this advanced laboratory. It represents an exceptional opportunity for the Institute and CSU Pueblo to continue advancements in cannabis research and to provide great opportunities for students at CSU Pueblo.”
CSU Pueblo is home to a cannabis biology and chemistry degree program that provides students with an understanding of basic chemical and biological principles that can be applied to the emerging field of cannabis science. The collaboration will support the advancement of biomedical research to evaluate the effects of certain isolated components from hemp/cannabis in diverse therapeutic areas and human consumption.
“This collaboration brings together VEI’s intellectual property and the expertise in research and development of the respective parties, to provide advancement in analysis standardization and the regulatory framework processes. The uniformity of standards and sustained compliance in testing, tracking, tracing, and certification of cannabinoids will ensure the public health and public safety while supporting the accelerated advancement of medical solutions within the hemp/cannabis industry,” said Dr. Elias Jackson, head of Government and Scientific Affairs for Vyripharm Enterprises.